IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biolopsją chłoniak B-komórkowy w ośrodkowym układzie nerwowym
- •Choroba nawrotowa lub oporna po co najmniej jednym wcześniejszym leczeniu metotreksatem w wysokiej dawce
- •Co najmniej jedno widoczne na rezonansie zmiany o średnicy co najmniej 1 cm
- •Ogólny stan zdrowia na poziomie 0-2 w skali ECOG
- •Prawidłowe wyniki badań krwi, nerek i wątroby
- •Zgoda na stosowanie antykoncepcji zgodnie z wymogami badania
✗ Disqualifies
- •Chłoniak wyłącznie w oku lub kręgosłupie bez zmian w mózgu
- •Inny typ chłoniaka niż B-komórkowy
- •Chłoniak rozprzestrzeniony poza ośrodkowy układ nerwowy
- •Brak odpowiedzi na temozolomid w ostatnim leczeniu
- •Równoczesne przyjmowanie wysokich dawek kortykosteroidów (z wyjątkami)
- •Inne aktywne nowotwory wymagające leczenia systemowego
- •Niezdolność do łykania tabletek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (36)
Mayo Clinic Cancer Center
Phoenix, United States
HonorHealth Cancer Center
Scottsdale, United States
Providence Medical Foundation
Fullerton, United States
UC Irvine Health
Orange, United States
Yale Cancer Center
New Haven, United States
John Hopkins University
Washington D.C., United States
University of Florida Gainesville
Gainesville, United States
Mayo Clinic Cancer Center
Jacksonville, United States
University of Maryland
Baltimore, United States
Massachusetts General Hospital
Boston, United States
Beth Israel Deaconess Medical Center
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Mayo Clinic Cancer Center
Rochester, United States
Hackensack University Medical Center
Hackensack, United States
Atlantic Health Overlook Medical Center
Summit, United States
NYU Langone Health
New York, United States
Columbia University Irving Medical Center
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Duke University Medical Center
Durham, United States
Providence Neurological Specialties West
Portland, United States
Penn State Health Milton S Hershey Medical Center
Hershey, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Rhode Island Hospital
Providence, United States
University of Washington
Seattle, United States
Epworth Healthcare
Melbourne, Australia
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil
University Hospital Ostrava
Ostrava, Czechia
University Hospital Královské Vinohrady
Prague, Czechia
Hôpitaux de Marseille
Marseille, France
Hospital Center University De Montpellier
Montpellier, France
ASST Spedali Civili di Brescia
Brescia, Italy
IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST
Meldola, Italy
Arcispedale S. Maria Nuova
Reggio Emilia, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Trial contact
Clinical Team
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.